NCT01461538

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Seagen Inc. · Industry
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Conditions

• Acute Lymphoid Leukemia
• Acute Myeloid Leukemia
• Anemia, Refractory, With Excess of Blasts
• Solid Tumors

Interventions

Type	Name	Description
DRUG	brentuximab vedotin	1.8 mg/kg every 3 weeks by intravenous (IV) infusion
DRUG	brentuximab vedotin	2.4 mg/kg every 3 weeks by intravenous (IV) infusion
DRUG	brentuximab vedotin	1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion

Timeline

• Start date: 2011-10-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2011-10-28
• Last updated: 2016-03-04
• Results posted: 2016-03-04

Locations

29 sites across 1 country: United States